Alnylam Pharmaceuticals announced on July 30, 2026, that it lowered its full-year 2026 sales guidance for its TTR product by about $200 million due to slower than expected market growth. This caused the stock to fall 28.31%, injuring investors. On October 29, 2026, the company reported weaker third-quarter demand and further lowered revenue expectations, leading to another sharp share decline. Law firm Glancy Prongay Wolke & Rotter LLP is investigating whether Alnylam misled investors, offering a potential path for investors to recover losses.
Alnylam Pharmaceuticals shares are currently priced at USD 176.58 on Pluang as of October 30, 2026, 04:41 WIB. The stock experienced a 24.02% decline in one day, reflecting continued market pressure. Despite this, the typical hold time for ALNY investors on Pluang is 41 days, with 81% of recent orders being buys.
Alnylam Pharmaceuticals held an RNAi roundtable to discuss Brezosiran (ALN-HTT02), a drug in development for Huntington's disease. Experts including Alnylam's research leaders and Dr. Gill Bates from University College London explained the importance...
Alnylam Pharmaceuticals announced a 105.7% year-on-year increase in Q2 sales of its drug Amvuttra, reaching about $1.1 billion. The company also shared encouraging clinical data for brezosiran, a treatment under development for Huntington’s disease. ...
